

# Job A J Verdonschot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/262516/publications.pdf>

Version: 2024-02-01

40  
papers

1,281  
citations

430754

18  
h-index

377752

34  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 321-331.	2.9	16
2	Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry. <i>ESC Heart Failure</i> , 2022, 9, 1463-1470.	1.4	9
3	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial. <i>European Journal of Heart Failure</i> , 2022, 24, 771-778.	2.9	7
4	The HFA-PEFF score identifies "early" HFpEF™ phenogroups associated with distinct biomarker profiles. <i>ESC Heart Failure</i> , 2022, 9, 2032-2036.	1.4	6
5	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e024505.	1.6	21
6	Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant. <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121009352.	1.6	9
7	Evaluation of the Interaction of Sex Hormones and Cardiovascular Function and Health. <i>Current Heart Failure Reports</i> , 2022, 19, 200-212.	1.3	15
8	Interatrial Block Predicts Life-Threatening Arrhythmias in Dilated Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
9	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. <i>European Heart Journal</i> , 2021, 42, 162-174.	1.0	62
10	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial. <i>European Journal of Heart Failure</i> , 2021, 23, 302-309.	2.9	24
11	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	4
12	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021, 9, 268-277.	1.9	46
13	Parvovirus B19 DNA detectable in hearts of patients with dilated cardiomyopathy, but absent or inactive in blood. <i>ESC Heart Failure</i> , 2021, 8, 2723-2730.	1.4	5
14	Clinical impact of re-evaluating genes and variants implicated in dilated cardiomyopathy. <i>Genetics in Medicine</i> , 2021, 23, 2186-2193.	1.1	17
15	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 1276-1286.	2.9	14
16	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy. A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 933-944.	2.9	34
17	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , 2021, 8, 3512-3520.	1.4	11
18	A global longitudinal strain cutoff value to predict adverse outcomes in individuals with a normal ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 4343-4345.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 163.	2.7	7
20	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMics™ in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021, 42, 684-696.	1.0	77
21	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	3
22	Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2020, 26, 212-222.	0.7	22
23	Value of Speckle Tracking-Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 549-558.	2.3	40
24	Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008727.	2.1	6
25	Implications of Genetic Testing in Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 476-487.	1.6	52
26	Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients. <i>Circulation</i> , 2020, 142, 1230-1232.	1.6	7
27	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. <i>European Journal of Heart Failure</i> , 2020, 22, 1586-1597.	2.9	16
28	A mutation update for the <i>FLNC</i> gene in myopathies and cardiomyopathies. <i>Human Mutation</i> , 2020, 41, 1091-1111.	1.1	92
29	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1711-1723.	2.9	43
30	Mutations in <i>PDLIM5</i> are rare in dilated cardiomyopathy but are emerging as potential disease modifiers. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2020, 8, e1049.	0.6	11
31	Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. <i>Journal of the American Heart Association</i> , 2019, 8, e012514.	1.6	39
32	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005897.	1.6	63
33	Parvovirus B19 in Dilated Cardiomyopathy: There Is More Than Meets the Eye. <i>Journal of Cardiac Failure</i> , 2019, 25, 64-66.	0.7	8
34	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004228.	1.6	65
35	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. <i>European Heart Journal</i> , 2018, 39, 864-873.	1.0	132
36	Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004682.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e005220.	1.6	51
38	Heart Failure With Recovered Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1557-1558.	1.2	20
39	Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature. <i>European Journal of Heart Failure</i> , 2016, 18, 1430-1441.	2.9	108
40	Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1313-1323.	1.2	76